摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

NCGC00380287-01_C28H33NO7_(1E,4S,6R,7E,11aS,14S,14aS,15S,15aR,16aS,16bS)-14-Benzyl-6-hydroxy-4,6,15,15a-tetramethyl-3,13,14,14a,15,15a,16a,16b-octahydro[1,3]dioxacyclotridecino[4,5-d]oxireno[f]isoindole-5,10,12(4H,6H)-trione | 36011-19-5

中文名称
——
中文别名
——
英文名称
NCGC00380287-01_C28H33NO7_(1E,4S,6R,7E,11aS,14S,14aS,15S,15aR,16aS,16bS)-14-Benzyl-6-hydroxy-4,6,15,15a-tetramethyl-3,13,14,14a,15,15a,16a,16b-octahydro[1,3]dioxacyclotridecino[4,5-d]oxireno[f]isoindole-5,10,12(4H,6H)-trione
英文别名
(1S,7R,9S,13S,14S,16R,17S,18S,19S)-19-benzyl-7-hydroxy-7,9,16,17-tetramethyl-2,4,15-trioxa-20-azatetracyclo[11.8.0.01,18.014,16]henicosa-5,11-diene-3,8,21-trione
CAS
36011-19-5
化学式
C28H33NO7
mdl
——
分子量
495.6
InChiKey
LAJXCUNOQSHRJO-DDAXAKGKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    206 °C
  • 沸点:
    587.59°C (rough estimate)
  • 密度:
    1.2415 (rough estimate)
  • 溶解度:
    DMF:11mg/mL; DMF:PBS (pH7.2) (1:30):0.03 mg/ml; DMSO:10mg/mL;乙醇:2mg/mL
  • LogP:
    1.920 (est)
  • 颜色/状态:
    CRYSTALS FROM ACETONE-HEXANE
  • 稳定性/保质期:
    UNSTABLE IN CHLOROFORM SOLN & UNDER ACIDIC CONDITIONS.
  • 旋光度:
    SPECIFIC OPTICAL ROTATION: -25.6 DEG @ 25 °C/D (IN METHANOL); WEAK ABSORPTIONS BETWEEN 240 & 300 NM DUE IN PART TO THE PI BOND TO PI BOND* TRANSITION OF THE MONOSUBSTITUTED AROMATIC RING

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    36
  • 可旋转键数:
    2
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.535
  • 拓扑面积:
    115
  • 氢给体数:
    2
  • 氢受体数:
    7

ADMET

毒理性
  • 人类毒性摘录
在纯化的人外周血淋巴细胞中,微量的细胞松弛素A、B、E和D(0.01-10微摩尔浓度)能显著增强植物血凝素(PHA)和刀豆蛋白A(Con A)引起的传输和代谢反应,包括对DNA合成、环磷酸腺苷积累、磷脂酰肌醇转换以及钠依赖性氨基酸运输的影响。
IN PURIFIED HUMAN PERIPHERAL BLOOD LYMPHOCYTES, LOW (0.01-10 MUMOL) CONCN OF CYTOCHALASINS A, B, E, & D PRODUCED MARKED AUGMENTATION OF TRANSPORT & METABOLIC RESPONSES TO PHYTOHEMAGGLUTININ (PHA) & CONCANAVALIN A (CON A), INCLUDING EFFECTS ON DNA SYNTHESIS, CYCLIC AMP ACCUMULATION, PHOSPHATIDYLINOSITOL TURNOVER, & SODIUM-DEPENDENT AMINO ACID TRANSPORT.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 人类毒性摘录
用细胞松弛素E(CE)、细胞松弛素D(CD)、细胞松弛素B(CB)和二氢细胞松弛素D(H2CB)处理人类多形核白细胞(PMNS)会导致细胞形态改变和细胞移动性抑制。形态变化与非肌动纤维母细胞的报道相似:细胞变圆、出现zeiosis和分支状。通过定量分析延时录像带记录,PMNS的平均细胞速度降至0.1微米/分钟(对照组为7.3微米/分钟)。PMNS对乳胶珠的吞噬作用受到75%的抑制。
TREATMENT OF HUMAN POLYMORPHONUCLEAR LEUKOCYTES (PMNS) WITH CYTOCHALASIN E (CE), CYTOCHALASIN D (CD), CYTOCHALASIN B (CB), AND DIHYDROCYTOCHALASIN D (H2CB) RESULTS IN ALTERATION OF CELL MORPHOLOGY & INHIBITION OF CELL MOTILITY. MORPHOLOGICAL CHANGES ARE SIMILAR TO THOSE REPORTED FOR NONAMEBOID FIBROBLASTS: ROUNDING, ZEIOSIS, & ARBORIZATION. MEAN CELL VELOCITY OF PMNS, AS MEASURED BY QUANTITATIVE ANALYSIS OF TIME-LAPSE VIDEOTAPE RECORDINGS, WAS REDUCED TO 0.1 MUM/MIN (CONTROL, 7.3 MUM/MIN). PHAGOCYTOSIS BY PMNS, AS MEASURED BY PHAGOCYTOSIS OF LATEX BEADS, WAS INHIBITED BY 75%.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 人类毒性摘录
尚未有关于细胞松弛素类化合物的慢性毒性和致癌性的报告...尽管已经进行了许多细胞学研究,目前为止观察到的各种效应表明这些化合物对动物和人类健康的重要性。...一些细胞松弛素表现出的强烈急性毒性,以及产生细胞松弛素的真菌在自然界中的广泛存在,应在未来关于真菌毒素的研究中予以考虑。/细胞松弛素/
THERE HAS BEEN NO REPORT ON CHRONIC TOXICITY & CARCINOGENICITY OF CYTOCHALASINS... ALTHOUGH MANY CYTOLOGICAL STUDIES HAVE BEEN DONE, THE VARIETY OF EFFECTS THUS FAR OBSERVED INDICATE THE IMPORTANCE OF THE COMPOUNDS FOR ANIMAL & HUMAN HEALTH. ...STRONG ACUTE TOXICITIES EXHIBITED BY SOME CYTOCHALASINS & THE WIDE NATURAL OCCURRENCE OF THE FUNGI THAT PRODUCE CYTOCHALASINS SHOULD BE CONSIDERED IN FUTURE STUDIES ON MYCOTOXINS. /CYTOCHALASINS/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 非人类毒性摘录
细胞松弛素对哺乳动物细胞的影响:其中一些更显著的影响被归类为形态学的,例如细胞骨架变异、多核化、弥漫性细胞器改变、核突出以及表面现象如膜皱褶减少。其他影响被描述为功能性的或生理性的,包括抑制细胞运动、有丝分裂繁殖、吞噬作用和胞饮作用;改变表面粘附性和微丝;合成减少;以及膜组分的摄取。这些研究主要使用细胞松弛素B,偶尔使用细胞松弛素A、D(接合孢子形成素A)和E。
EFFECTS OF CYTOCHALASINS ON MAMMALIAN CELLS: AMONG THE MORE PROMINENT EFFECTS ARE SEVERAL WHICH ARE CHARACTERIZED AS MORPHOLOGICAL IN NATURE, SUCH AS CYTOSKELETAL VARIATION, MULTINUCLEATION, DIFFUSE ORGANELLE ALTERATION, NUCLEAR EXTRUSION, & SURFACE PHENOMENA SUCH AS DIMINISHED MEMBRANE RUFFLING. OTHER EFFECTS ARE DESCRIBED AS FUNCTIONAL OR PHYSIOLOGICAL, & INCLUDE INHIBITION OF CELL MOTILITY, MITOTIC REPRODUCTION, & PHAGOCYTOSIS & PINOCYTOSIS; ALTERATION OF SURFACE ADHESION PROPERTIES & MICROFILAMENTS; DEPRESSION OF SYNTHESIS; & UPTAKE OF MEMBRANE COMPONENTS. THESE STUDIES WERE PERFORMED MAINLY WITH CYTOCHALASIN B & OCCASIONALLY WITH CYTOCHALASIN A, D (ZYGOSPORING A), & E.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 非人类毒性摘录
细胞松弛素E很少产生其他细胞松弛素典型的核挤出,然而,它在核周围产生一个独特的光环。
CYTOCHALASIN E RARELY PRODUCES NUCLEAR EXTRUSION TYPICAL OF OTHER CYTOCHALASINS; HOWEVER, IT PRODUCES A UNIQUE HALO AROUND THE NUCLEI.
来源:Hazardous Substances Data Bank (HSDB)

安全信息

  • 危险等级:
    6.1(a)
  • 危险品标志:
    T+,T
  • 安全说明:
    S28,S36/37,S45
  • 危险类别码:
    R26/27/28
  • WGK Germany:
    3
  • 海关编码:
    29349990
  • 危险品运输编号:
    UN 1544 6.1/PG 2
  • 包装等级:
    I
  • 危险类别:
    6.1(a)
  • 危险标志:
    GHS06,GHS08
  • 危险性描述:
    H300,H310,H330,H361
  • 危险性防范说明:
    P260,P264,P280,P284,P301 + P310,P302 + P350

SDS

SDS:c0f2313eba684982c7684beb059f18a6
查看

制备方法与用途

生物活性

Cytochalasin E 是一种含有曲霉衍生真菌代谢产物的环氧化物,能够抑制血管生成和肿瘤生长。它也是一种有效的肌动蛋白解聚剂,能结合肌动蛋白丝的倒刺端并覆盖它,从而防止肌动蛋白伸长。

体外研究

Cytochalasin E 在剂量依赖性的方式下显著抑制 A549 细胞的生长,并且能够诱导自噬相关蛋白 (LC3-II) 和 SQSTM1/p62 的上调。

同类化合物

胞松弛素D 细胞松驰素J 细胞松驰素C 细胞松驰素 E 细胞松驰素 A 细胞松弛素H 细胞松弛素B 球毛壳菌素K 球毛壳菌素 F 球毛壳菌素 C 毛壳球菌素 松胞菌素 F 曲霉菌素PZ 接柄孢素E 接柄孢素D 噻氯匹定N-氧化物 二氢细胞松弛素 3-吡啶胺,6-乙氧基-4-甲基- (7S,13E,16S,18R,19E,21R)-7-乙酰氧基-18,21-二羟基-16,18-二甲基-10-苯基[11]松胞素-6(12),13,19-三烯-1,17-二酮 (7S,13E,16S,18R,19E,21R)-7,18,21-三羟基-16,18-二甲基-10-苯基-(11)松胞素-5,13,19-三烯-1-酮 (7S,13E,16S,18R,19E,21R)-21-(乙酰氧基)-7,18-二羟基-16,18-二甲基-10-苯基-(11)松胞素-5,13,19-三烯-1-酮 (6S,7S,13E,16S,18R,19E,21R)-21-(乙酰氧基)-6,7,18-三羟基-16,18-二甲基-10-苯基-(11)松胞素-13,19-二烯-1-酮 (3S,3aR,4S,6aS,7E,15aS)-3,3a,4,6a,9,10,13,14-八氢-4,5,8-三甲基-3-(2-甲基丙基)-1H-环十一碳(d)异吲哚-1,11,12,15(2H)-四酮 (3S,3aR,4S,6aS,7E,11S,13E,15aS)-2,3,3a,4,6a,9,10,11-八氢-11-羟基-4,5,8-三甲基-3-(2-甲基丙基)-1H-环十一碳(d)异吲哚-1,12,15-三酮 [(1R,2R,3E,5R,7S,9E,11R,14S,15R,16S)-16-benzyl-5,12-dihydroxy-5,7,14-trimethyl-13-methylidene-6,18-dioxo-17-azatricyclo[9.7.0.01,15]octadeca-3,9-dien-2-yl] acetate deacetylcytochalasin C 19-O-acetylchaetoglobosin A 2H-Oxacyclotetradecino[2,3-d]isoindole-2,18(5H)-dione,6,7,8,9,10,12a,13,14,15,15a,16,17-dodecahydro-5,13-dihydroxy-9,15-dimethyl-14-methylene-16-(phenylmethyl)-,(3E,5R,9R,11E,12aS,13S,15S,15aS,16S,18aS)- aspochalasin D Dihydrocytochalasinb (1S,10R,14S,15S,17S,18S,19S)-19-benzyl-15-hydroxy-10,17-dimethyl-16-methylidene-2-oxa-20-azatricyclo[12.7.0.01,18]henicosa-4,12-diene-3,6,21-trione Cytochalasin O Aspochalasin-B 21-O-Octanoylepoxycytochalasin J Dihydrocytochalasin B (7S,13E,16S,17R,18R)-2-Benzoyl-7-tert-butyldimethylsilyloxy-17,18-dihydroxy-16,18-dimethyl-10-phenyl[11]cytochalasa-6(12),13-diene-1,21-dione 7-O-acetylcytochalasin D 21,23-Dioxa[13]cytochalasa-13,19-diene-1,17,22-trione, 6,7-epoxy-18-hydroxy-16,18-dimethyl-10-phenyl-, (7S,13E,16S,18R,19E)- (4Z,12E)-19-benzyl-15-hydroxy-10,17-dimethyl-16-methylidene-2-oxa-20-azatricyclo[12.7.0.01,18]henicosa-4,12-diene-3,7,21-trione Zygosporin A Acetic acid (3Z,9E)-16-benzyl-5,12-dihydroxy-5,7,14-trimethyl-13-methylene-18-oxo-17-aza-tricyclo[9.7.0.01,15]octadeca-3,9-dien-2-yl ester Cytochalasa-6(12),13,19-triene-1,17,21-trione, 7-(acetyloxy)-16,18-dimethyl-18-hydroxy-10-phenyl-, (13E,16S,18R,19E,21R)- Cytochalasin j Zygosporin G Cytochalasa-6(12),13-diene-1,17,21-trione, 19-(ethylthio)-7,18-dihydroxy-16,18-dimethyl-10-phenyl-, (7-beta,13E,16S,18R)- Cytochalasa-6(12),13-diene-1,17,21-trione, 7-(acetyloxy)-18-hydroxy-19-methoxy-16,18-dimethyl-10-phenyl-, (7-beta,13E,16S,18R)- Deacetylcytochalasin H (7Z,9S,11E,13R,14S,16R,17S,18R,19S)-19-(1H-Indol-3-ylmethyl)-7,9,16,17-tetramethyl-15-oxa-20-azatetracyclo[11.8.0.01,18.014,16]henicosa-7,11-diene-2,5,6,21-tetrone 1H-Cycloundec(d)isoindole-1,15(2H)-dione, 3,3a,4,6a,9,10,11,12-octahydro-11,12-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-, (3S,3aR,4S,6aS,7E,11S,12S,13E,15aS)- 10H-Cycloundec(d)oxireno(f)isoindol-10-one, 9-(acetyloxy)-3,4,5,6,9,11,12,12a,13,13a,14a,14b-dodecahydro-6-hydroxy-4,6,13,13a-tetramethyl-12-(phenylmethyl)-, (1E,4S,6R,7E,9R,9aR,12S,12aR,13S,13aR,14aS,14bR)-